MC-Val-Cit-PAB-Amide-TLR7 agonist 4

Cat. No.: HY-145960: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate.

연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.

MC-Val-Cit-PAB-Amide-TLR7 agonist 4 화학구조

CAS No. : 2413016-49-4

사이즈	재고	수량
1 mg	견적 받기 2 - 3 weeks 1-2 weeks 3 - 4 weeks 2-3 weeks	Estimated Time of Arrival: December 31
5 mg	견적 받기 2 - 3 weeks 1-2 weeks 3 - 4 weeks 2-3 weeks	Estimated Time of Arrival: December 31
10 mg	견적 받기 2 - 3 weeks 1-2 weeks 3 - 4 weeks 2-3 weeks	Estimated Time of Arrival: December 31
25 mg	견적 받기 2 - 3 weeks 1-2 weeks 3 - 4 weeks 2-3 weeks	Estimated Time of Arrival: December 31
50 mg	견적 받기 2 - 3 weeks 1-2 weeks 3 - 4 weeks 2-3 weeks	Estimated Time of Arrival: December 31
100 mg	견적 받기
200 mg	견적 받기

Synthetic products have potential research and development risk.

or 대량구매 문의

* 장바구니에 담기 전 물품의 수량을 선택해 주십시오.

This product is a controlled substance and not for sale in your territory.

고객리뷰

Based on 1 Customer Validation

Other Forms of MC-Val-Cit-PAB-Amide-TLR7 agonist 4:

MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic In-stock

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

View All EGFR Isoform Specific Products:

View All Isoforms

EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

View All Toll-like Receptor (TLR) Isoform Specific Products:

View All Isoforms

TLR3 TLR8 TLR9 TLR2 TLR4 TLR7 TLR1 TLR6

Biological Activity
순도&문서
References
고객리뷰

제품 설명

MC-Val-Cit-PAB-Amide-TLR7 agonist 4 (example 15) is a HER2-TLR7 and HER2-TLR8 immune agonist conjugate^[1].

IC₅₀ & Target

HER2

TLR7

TLR8

분자량

1041.20

화학식

C₅₂H₇₂N₁₂O₁₁

CAS No.

2413016-49-4

Appearance

Solid

Color

White to off-white

SMILES

O=C(C=CC1=O)N1CCCCCC(N[C@H](C(N[C@H](C(NC2=CC=C(COC(NC(C)(C)C(NCCOC(C)(C)CN3C(C4=CC=CC=C4N=C5N)=C5N=C3COCC)=O)=O)C=C2)=O)CCCNC(N)=O)=O)C(C)C)=O

선적

Room temperature in continental US; may vary elsewhere.

보관

Powder	-20°C	3 years
	4°C	2 years

*The compound is unstable in solutions, freshly prepared is recommended.

순도&문서

Purity: 99.39%

Select Batch:

Data Sheet (265 KB) SDS (252 KB)

COA (247 KB) HNMR (214 KB) RP-HPLC (206 KB) LCMS (269 KB)

Handling Instructions (2659 KB)

References

[1]. Valerie Odegard, et al. Compositions for the treatment of disease with immune stimulatory conjugates. WO2020056008 A1.